Assessing pricing and affordability of HBV treatment in Asia-Pacific region: a barrier to elimination

Chen J 1 , Jia J 2 , Zhuang H 3 , Zhang W 4 , Yang JM 5 , Tanwandee T 6 Show all authors , Payawal D 7 , Hamid S 8 , Sarin SK 9 , Omata M 10 , Wang G 11 , Lau G 12 , Apasl Viral Elimination Task Force

Affiliations 

  • 1 JC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China. jingchen001@cuhk.edu.hk
  • 2 Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
  • 3 Department of Microbiology and Centre for Infectious Diseases, Peking University Health Science Centre, Beijing, China
  • 4 Department of Infectious Diseases, National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, 200040, China
  • 5 Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea
  • 6 Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 7 Department of Medicine, Cardinal Santos Medical Center, Mandaluyong, Philippines
  • 8 Aga Khan University, Karachi, 74800, Pakistan
  • 9 Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
  • 10 Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-Shi, Yamanashi, 400-8506, Japan
  • 11 Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China
  • 12 Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, 14F/21F,9 Queen's Road Central, Central, Hong Kong SAR, China. gkklau@hnhmgl.com
Hepatol Int, 2025 Feb 03.
PMID: 39900677 DOI: 10.1007/s12072-024-10744-9

Abstract

BACKGROUND: The Asia-Pacific (AP) region carries a substantial burden of HBV. Affordable HBV treatment is crucial to attain WHO's elimination goal. This study assesses the pricing and affordability of HBV treatment in AP.

METHODS: A survey conducted among APASL members from 2 Aug to 30 Oct, 2023, gathered data on antiviral HBV drugs, treatment costs covering stages of chronic hepatitis B (CHB), compensated cirrhosis (CC), hepatocellular carcinoma (HCC), liver transplant, and monitoring expenses. Drug costs for TDF and ETV were compared to international reference price (TDF: $30, ETV: $36 per person per year), generating a median price ratio (MPR) where MPR 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications